The Latin America, Middle East and Africa Vaccine Adjuvants Market would witness market growth of 6.0% CAGR during the forecast period (2023-2030).
Widely employed adjuvants, including oil-in-water emulsions and aluminum compounds, are widely acknowledged to elicit more robust antibody responses to vaccine antigens. The capacity of adjuvants to increase total antibody titers and the number of functional antibodies, antibodies with greater affinity for vaccine antigens, or both, is recognized with more attention.
A growing number of vaccines in development are incorporating adjuvants due to the numerous benefits such agents provide, including facilitating the use of lower doses of antigen, enhancing the adaptive response to a vaccine, and directing the type of adaptive response that produces the highest level of immunity for each specific pathogen. Moreover, while most adjuvants utilized in vaccines primarily stimulate humoral immunity, several innovative adjuvants currently undergoing clinical or preclinical research aim to augment particular subtypes of T-cell responses to elicit comprehensive immune reactions necessary for intricate indications like HIV-AIDS and malaria.
The Middle East has grappled with a notable rise in the prevalence of infectious diseases, presenting a complex healthcare challenge across the region. Several factors contribute to this surge. Urbanization, swift population growth, and inadequate sanitation in some areas have created conditions conducive to the spread of infectious pathogens. Rapid urban expansion often leads to overcrowding, compromised hygiene standards, and limited access to clean water, amplifying the risk of disease transmission within communities. Consequently, the increasing incidence of communicable diseases in this region drives the expansion of the market.
The Brazil market dominated the LAMEA Vaccine Adjuvants Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $29.4 Million by 2030. The Argentina market is showcasing a CAGR of 6.6% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 5.7% during (2023 - 2030).
Based on Type, the market is segmented into Particulate, Adjuvant Emulsion, Pathogen, Combination, and Others. Based on Administration, the market is segmented into Intramuscular, Intranasal, Oral, Intradermal, and Others. Based on Application, the market is segmented into Infectious Diseases, Cancer, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Vaccine Adjuvants Market is Projected to reach USD 2.1 Billion by 2030, at a CAGR of 3.7%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC, Novavax, Inc., SPI Pharma, Inc. (Associated British Foods PLC), Agenus Inc., CSL Limited, InvivoGen SAS, Croda International PLC, Seppic S.A. (L’Air Liquide S.A.), Merck & Co., Inc. and Riboxx GmbH
Scope of the Study
Market Segments Covered in the Report:
By Type
- Particulate
- Adjuvant Emulsion
- Pathogen
- Combination
- Others
By Administration
- Intramuscular
- Intranasal
- Oral
- Intradermal
- Others
By Application
- Infectious Diseases
- Cancer
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- GlaxoSmithKline PLC
- Novavax, Inc.
- SPI Pharma, Inc. (Associated British Foods PLC)
- Agenus Inc.
- CSL Limited
- InvivoGen SAS
- Croda International PLC
- Seppic S.A. (L’Air Liquide S.A.)
- Merck & Co., Inc.
- Riboxx GmbH
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Vaccine Adjuvants Market, by Type
1.4.2 LAMEA Vaccine Adjuvants Market, by Administration
1.4.3 LAMEA Vaccine Adjuvants Market, by Application
1.4.4 LAMEA Vaccine Adjuvants Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Trials and Approvals
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2020, Feb – 2023, Oct) Leading Players
4.4 Porter Five Forces Analysis
Chapter 5. LAMEA Vaccine Adjuvants Market, by Type
5.1 LAMEA Particulate Market, by Country
5.2 LAMEA Adjuvant Emulsion Market, by Country
5.3 LAMEA Pathogen Market, by Country
5.4 LAMEA Combination Market, by Country
5.5 LAMEA Others Market, by Country
Chapter 6. LAMEA Vaccine Adjuvants Market, by Administration
6.1 LAMEA Intramuscular Market, by Country
6.2 LAMEA Intranasal Market, by Country
6.3 LAMEA Oral Market, by Country
6.4 LAMEA Intradermal Market, by Country
6.5 LAMEA Others Market, by Country
Chapter 7. LAMEA Vaccine Adjuvants Market, by Application
7.1 LAMEA Infectious Diseases Market, by Country
7.2 LAMEA Cancer Market, by Country
7.3 LAMEA Others Market, by Country
Chapter 8. LAMEA Vaccine Adjuvants Market, by Country
8.1 Brazil Vaccine Adjuvants Market
8.1.1 Brazil Vaccine Adjuvants Market, by Type
8.1.2 Brazil Vaccine Adjuvants Market, by Administration
8.1.3 Brazil Vaccine Adjuvants Market, by Application
8.2 Argentina Vaccine Adjuvants Market
8.2.1 Argentina Vaccine Adjuvants Market, by Type
8.2.2 Argentina Vaccine Adjuvants Market, by Administration
8.2.3 Argentina Vaccine Adjuvants Market, by Application
8.3 UAE Vaccine Adjuvants Market
8.3.1 UAE Vaccine Adjuvants Market, by Type
8.3.2 UAE Vaccine Adjuvants Market, by Administration
8.3.3 UAE Vaccine Adjuvants Market, by Application
8.4 Saudi Arabia Vaccine Adjuvants Market
8.4.1 Saudi Arabia Vaccine Adjuvants Market, by Type
8.4.2 Saudi Arabia Vaccine Adjuvants Market, by Administration
8.4.3 Saudi Arabia Vaccine Adjuvants Market, by Application
8.5 South Africa Vaccine Adjuvants Market
8.5.1 South Africa Vaccine Adjuvants Market, by Type
8.5.2 South Africa Vaccine Adjuvants Market, by Administration
8.5.3 South Africa Vaccine Adjuvants Market, by Application
8.6 Nigeria Vaccine Adjuvants Market
8.6.1 Nigeria Vaccine Adjuvants Market, by Type
8.6.2 Nigeria Vaccine Adjuvants Market, by Administration
8.6.3 Nigeria Vaccine Adjuvants Market, by Application
8.7 Rest of LAMEA Vaccine Adjuvants Market
8.7.1 Rest of LAMEA Vaccine Adjuvants Market, by Type
8.7.2 Rest of LAMEA Vaccine Adjuvants Market, by Administration
8.7.3 Rest of LAMEA Vaccine Adjuvants Market, by Application
Chapter 9. Company Profiles
9.1 Novavax, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expenses
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.6 SWOT Analysis
9.2 SPI Pharma, Inc. (Associated British Foods PLC)
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.3 Agenus Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Regional Analysis
9.3.4 Research & Development Expenses
9.3.5 Recent strategies and developments:
9.3.5.1 Partnerships, Collaborations, and Agreements:
9.3.6 SWOT Analysis
9.4 InvivoGen SAS
9.4.1 Company Overview
9.4.2 SWOT Analysis
9.5 Seppic S.A. (L’Air Liquide S.A.)
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expenses
9.5.5 Recent strategies and developments:
9.5.5.1 Product Launches and Product Expansions:
9.5.6 SWOT Analysis
9.6 Riboxx GmbH
9.6.1 Company Overview
9.7 GlaxoSmithKline PLC (GSK)
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Product Launches and Product Expansions:
9.7.5.3 Trials and Approvals:
9.7.6 SWOT Analysis
9.8 CSL Limited
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.8.6 SWOT Analysis
9.9 Croda International PLC
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Recent strategies and developments:
9.9.4.1 Partnerships, Collaborations, and Agreements:
9.9.4.2 Acquisition and Mergers:
9.10. Merck & Co., Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expenses
9.10.5 Recent strategies and developments:
9.10.5.1 Acquisition and Mergers:
9.10.6 SWOT Analysis
TABLE 1 LAMEA Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 2 LAMEA Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Vaccine Adjuvants Market
TABLE 4 Product Launches And Product Expansions– Vaccine Adjuvants Market
TABLE 5 Acquisition and Mergers– Vaccine Adjuvants Market
TABLE 6 Trials and Approvals- Vaccine Adjuvants Market
TABLE 7 LAMEA Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 8 LAMEA Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 9 LAMEA Particulate Market, by Country, 2019 - 2022, USD Million
TABLE 10 LAMEA Particulate Market, by Country, 2023 - 2030, USD Million
TABLE 11 LAMEA Adjuvant Emulsion Market, by Country, 2019 - 2022, USD Million
TABLE 12 LAMEA Adjuvant Emulsion Market, by Country, 2023 - 2030, USD Million
TABLE 13 LAMEA Pathogen Market, by Country, 2019 - 2022, USD Million
TABLE 14 LAMEA Pathogen Market, by Country, 2023 - 2030, USD Million
TABLE 15 LAMEA Combination Market, by Country, 2019 - 2022, USD Million
TABLE 16 LAMEA Combination Market, by Country, 2023 - 2030, USD Million
TABLE 17 LAMEA Others Market, by Country, 2019 - 2022, USD Million
TABLE 18 LAMEA Others Market, by Country, 2023 - 2030, USD Million
TABLE 19 LAMEA Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 20 LAMEA Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 21 LAMEA Intramuscular Market, by Country, 2019 - 2022, USD Million
TABLE 22 LAMEA Intramuscular Market, by Country, 2023 - 2030, USD Million
TABLE 23 LAMEA Intranasal Market, by Country, 2019 - 2022, USD Million
TABLE 24 LAMEA Intranasal Market, by Country, 2023 - 2030, USD Million
TABLE 25 LAMEA Oral Market, by Country, 2019 - 2022, USD Million
TABLE 26 LAMEA Oral Market, by Country, 2023 - 2030, USD Million
TABLE 27 LAMEA Intradermal Market, by Country, 2019 - 2022, USD Million
TABLE 28 LAMEA Intradermal Market, by Country, 2023 - 2030, USD Million
TABLE 29 LAMEA Others Market, by Country, 2019 - 2022, USD Million
TABLE 30 LAMEA Others Market, by Country, 2023 - 2030, USD Million
TABLE 31 LAMEA Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 32 LAMEA Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 33 LAMEA Infectious Diseases Market, by Country, 2019 - 2022, USD Million
TABLE 34 LAMEA Infectious Diseases Market, by Country, 2023 - 2030, USD Million
TABLE 35 LAMEA Cancer Market, by Country, 2019 - 2022, USD Million
TABLE 36 LAMEA Cancer Market, by Country, 2023 - 2030, USD Million
TABLE 37 LAMEA Others Market, by Country, 2019 - 2022, USD Million
TABLE 38 LAMEA Others Market, by Country, 2023 - 2030, USD Million
TABLE 39 LAMEA Vaccine Adjuvants Market, by Country, 2019 - 2022, USD Million
TABLE 40 LAMEA Vaccine Adjuvants Market, by Country, 2023 - 2030, USD Million
TABLE 41 Brazil Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 42 Brazil Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 43 Brazil Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 44 Brazil Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 45 Brazil Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 46 Brazil Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 47 Brazil Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 48 Brazil Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 49 Argentina Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 50 Argentina Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 51 Argentina Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 52 Argentina Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 53 Argentina Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 54 Argentina Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 55 Argentina Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 56 Argentina Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 57 UAE Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 58 UAE Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 59 UAE Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 60 UAE Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 61 UAE Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 62 UAE Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 63 UAE Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 64 UAE Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 65 Saudi Arabia Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 66 Saudi Arabia Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 67 Saudi Arabia Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 68 Saudi Arabia Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 69 Saudi Arabia Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 70 Saudi Arabia Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 71 Saudi Arabia Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 72 Saudi Arabia Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 73 South Africa Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 74 South Africa Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 75 South Africa Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 76 South Africa Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 77 South Africa Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 78 South Africa Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 79 South Africa Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 80 South Africa Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 81 Nigeria Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 82 Nigeria Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 83 Nigeria Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 84 Nigeria Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 85 Nigeria Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 86 Nigeria Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 87 Nigeria Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 88 Nigeria Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 89 Rest of LAMEA Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 90 Rest of LAMEA Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 91 Rest of LAMEA Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 92 Rest of LAMEA Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 93 Rest of LAMEA Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 94 Rest of LAMEA Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 95 Rest of LAMEA Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 96 Rest of LAMEA Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 97 Key Information – Novavax, Inc.
TABLE 98 Key Information – SPI Pharma, Inc.
TABLE 99 Key Information – Agenus Inc.
TABLE 100 Key Information – InvivoGen SAS
TABLE 101 Key Information – Seppic S.A.
TABLE 102 Key Information – Riboxx GmbH
TABLE 103 Key Information – GlaxoSmithKline PLC
TABLE 104 Key Information – CSL Limited
TABLE 105 Key Information – Croda International PLC
TABLE 106 Key Information - Merck & Co., Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 LAMEA Vaccine Adjuvants Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting the Vaccine Adjuvants Market
FIG 4 KBV Cardinal Matrix
FIG 5 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 6 Key Strategic Move: (Product Launches and Product Expansions : 2017, Jun – 2021, Jun) Leading Players
FIG 7 Porter’s Five Forces Analysis – Vaccine Adjuvants Market
FIG 8 LAMEA Vaccine Adjuvants Market share, by Type, 2022
FIG 9 LAMEA Vaccine Adjuvants Market share, by Type, 2030
FIG 10 LAMEA Vaccine Adjuvants Market, by Type, 2019 - 2030, USD Million
FIG 11 LAMEA Vaccine Adjuvants Market share, by Administration, 2022
FIG 12 LAMEA Vaccine Adjuvants Market share, by Administration, 2030
FIG 13 LAMEA Vaccine Adjuvants Market, by Administration, 2019 - 2030, USD Million
FIG 14 LAMEA Vaccine Adjuvants Market share, by Application, 2022
FIG 15 LAMEA Vaccine Adjuvants Market share, by Application, 2030
FIG 16 LAMEA Vaccine Adjuvants Market, by Application, 2019 - 2030, USD Million
FIG 17 LAMEA Vaccine Adjuvants Market share, by Country, 2022
FIG 18 LAMEA Vaccine Adjuvants Market share, by Country, 2030
FIG 19 LAMEA Vaccine Adjuvants Market, by Country, 2019 - 2030, USD Million
FIG 20 SWOT Analysis: Novavax, Inc.
FIG 21 SWOT Analysis: Agenus Inc.
FIG 22 SWOT Analysis: InvivoGen SAS
FIG 23 SWOT Analysis: Seppic S.A.
FIG 24 Recent strategies and developments: GlaxoSmithKline PLC
FIG 25 SWOT Analysis: GlaxoSmithKline PLC
FIG 26 SWOT Analysis: CSL Limited
FIG 27 SWOT Analysis: Merck & Co., Inc.